Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease

Acta Neuropathologica

Volumn 100, Issue 2, 2000, Pages 205-212

  Marksteiner, J ^a   Lechner, T ^a   Kaufmann, W A ^a   Gurka, P ^a   Humpel, C ^a   Nowakowski, C ^a   Maier, H ^c   Jellinger, K A ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c NONE

Author keywords

Alzheimer's disease; Chromogranin B; Hippocampus; Human brain; Synapse loss

Indexed keywords

CHROMOGRANIN B;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL VACUOLE; CLINICAL ARTICLE; COGNITIVE DEFECT; DENTATE GYRUS; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MOSSY FIBER; NERVE FIBER; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SYNAPSE;

EID: 0033949105     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004010000239     Document Type: Article

References (37)

1. Behan DP, Khongsaly O, Owens MJ, Chung HD, Nemeroff CB, De Souza EB (1997) Corticotropin-releusing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in Alzheimer's disease and control postmortem human brain. J Neurochem 68: 2053-2060
2. Benjannet S, Leduc R, Adrouche N, Falgueyret JP, Marcinkiewicz M, Seidah NG, Mbikay M, Lazure C, Chretien M (1987) Chromogranin B (secretogranin I), a putative precursor of two novel pituitary peptides through processing at paired basic residues. FEBS Lett 224: 142-148
3. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259
4. Chanat E, Weiss U, Huttner WB, Tooze SA (1993) Reduction of the disulfide bond of chromogranin B (secretogranin I) in the trans-Golgi network causes its missorting to the constitutive secretory pathways. EMBO J 12: 2159-2168
5. Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr 10: 11-23
6. Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V (1999) Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry 56: 981-987
7. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16: 285-298
8. Erickson JD, Lloyd R, Trojanowski JQ, Iacangelo A, Eiden E (1992) Sites of synthesis of chromogranins A and B in the human brain. Neuropeptides 21: 239-244
9. Fischer-Colbrie R, Hagn C, Schober M (1987) Chromogranins A, B, and C: widespread constituents of secretory vesicles. Ann N Y Acad Sci 493: 120-134
10. Holstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
11. Forss-Petter S, Danielson P, Battenberg E, Bloom F, Sutcliffe JG (1989) Nucleotide sequence and cellular distribution of rat chromogranin B (secretogranin I) mRNA. J Mol Neurosci 1: 63-75
12. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL (1996) Neuropeptide deficits in schizophrenia vs Alzheimer's disease cerebral cortex. Biol Psychiatry 39: 82-91
13. Heinonen O, Soininen H, Sorvari H, Kosunen O, Paljarvi L, Koivisto E, Riekkinen PJS (1995) Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease. Neuroscience 64: 375-384
14. Husain MM, Nemeroff CB (1990) Neuropeptides and Alzheimer's disease. J Am Geriatr Soc 38: 918-925
15. Huttner WB, Gerdes HH, Rosa P (1991) The granin (chromogranin/secretogranin) family. Trends Biochem Sci 16: 27-30
16. Hyman BT (1998) New neuropathological criteria for Alzheimer disease [editorial]. Arch Neurol 55: 1174-1176
17. Jellinger KA (1997) Neuropathological staging of Alzheimer-related lesions: the challenge of establishing relations to age. Neurobiol Aging 18: 369-375
18. Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 54: 77-95
19. Kaufmann WA, Barnas U, Humpel C, Nowakowski K, DeCol C, Gurka P, Ransmayr G, Hinterhuber H, Winkler H, Marksteiner J (1998) Synaptic loss reflected by secretoneurin-like immunoreactivity in the human hippocampus in Alzheimers disease. Eur J Neurosci 10: 1084-1094
20. Khuchuturiun ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42: 1097-1105
21. Knowles RB, Gomez-Isla T, Hyman BT (1998) Aβ associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol 57: 1122-1130
22. Kroesen S, Marksteiner J, Leitner B, Hogue Angeletti R, Fischer Colbrie R, Winkler H (1996) Rat brain: distribution of immunoreactivity of PE-11, a peptide derived from chromogranin B. Eur J Neurosci 8: 2679-2689
23. Lassmann H, Weiler R, Fischer P, Bancher C, Jellinger K, Floor E, Danielczyk W, Seitelberger F, Winkler H (1992) Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience 46: 1-8
24. Marcinkiewicz M, Benjannet S, Seidah NG, Cantin M, Chrétien M (1985) Immunocytochemical localization of a novel pituitary protein (7B2) within the rat brain and hypophysis. J Histochem Cytochem 33: 1219-1226
25. Marksteiner J, Bauer R, Kaufmann WA, Weiss E, Barnas U, Maier J (1999) PE-11, a peptide derived from chromogranin B, in the human brain. Neuroscience 91: 1155-1170
26. Masliah E, Terry RD, Alford M, DeTeresa R, Hansen LA (1991) Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 138: 235-246
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the MINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944
28. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Belle G van, Berg L (1991) The consortium to establish a registry for Alzheimer's disease. Neurology 41: 479-486
29. Munoz DG (1990) The distribution of chromogranin A-like immunoreactivity in the human hippocampus coincides with the pattern of resistance to epilepsy-induced neuronal damage. Ann Neurol 27: 266-275
30. Reisberg B, Ferris SH, De Leon MJ, Crook T (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136-1139
31. Scheff SW, Price DA (1998) Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease. J Neuropathol Exp Neurol 57: 1146-1153
32. Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J (1997) Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. Biochem Biophys Res Commun 236: 239-242
33. Solodkin A, Van Hoesen GW (1996) Entorhinal cortex modules of the human brain. J Comp Neurol 365: 610-617
34. Sunderland T, Rubinow DR, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. Am J Psychiatry 144: 1313-1316
35. Thiele C, Huttner WB (1998) The disulfide-bonded loop of chromogranins, which is essential for sorting to secretory granules, mediates homodimerization. J Biol Chem 273: 1223-1231
36. Tierney MC, Fisher RH, Lewis ASJ, Zorzitto ML, Snow WG, Reid DW, Nieuwstraten P (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 38: 359-364
37. Zwieten EJ van, Ravid R, Swaab DF (1996) Differential vasopressin and oxytocin innervation of the human parabrachial nucleus: no changes in Alzheimer's disease. Brain Res 711: 146-152